Penpulimab-kcqx, a humanized IgG1 monoclonal anti–PD-1 antibody, extended progression-free survival to 9.6 months compared to 7.0 months with chemotherapy alone in patients with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma. The U.S. FDA approved penpulimab-kcqx in combination with cisplatin or carboplatin and gemcitabine as a first-line treatment, and as monotherapy for adults with metastatic nonkeratinizing NPC following progression on platinum-based chemotherapy and at least one additional systemic therapy. The agent received fast track, breakthrough therapy, and orphan drug designations from the FDA.

Source: FDA